ClinicalTrials.gg
Not yet recruitingNCT07442565SYNSTAR03Updated Mar 4, 2026

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

A Phase 3 interventional study of SYS6010 and Docetaxel in Non-Small Cell Lung Cancer, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 11 open to participants now, 12 under way, 7 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Planned enrollment
4th of 16
506 · median 365
Started
2026
with 3 others
Phase 3
7 of 17
6 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
14th of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 in phase 3, reaches primary completion later than 8 of the 11 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

This is a randomized, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of SYS6010 versus docetaxel in participants with Locally Advanced or Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer who Have Failed Standard Therapy. The primary Objective is to evaluate the efficacy of SYS6010 versus docetaxel in participants with EGFR wild-type locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Secondary Objectives includes safety, quality of life, immunogenicity, biomarkers, and efficacy correlations of SYS6010 compared to docetaxel in the same patient population.

Read the detailed description

This is a randomized, open-label, multicenter, Phase III clinical study designed to evaluate the efficacy and safety of SYS6010 compared with docetaxel in participants with locally advanced or metastatic EGFR wild-type nsq-NSCLC who have failed standard therapy.

Approximately 506 participants will be enrolled and randomized 1:1 to receive either SYS6010 or docetaxel. Randomization will be stratified by: (1) brain metastases (yes vs no) and (2) EGFR high expression (yes vs no). EGFR protein expression will be assessed by immunohistochemistry (IHC).

Key eligibility criteria include: age ≥18 years; histologically or cytologically confirmed locally advanced or metastatic nsq-NSCLC; and EGFR mutation negative confirmed for the EGFR wild-type population. For participants who are driver gene-negative, prior therapy must have included immunotherapy and platinum-based chemotherapy ± anti-angiogenic therapy with documented treatment failure. For participants who are driver gene-positive, prior therapy must have included appropriate targeted therapy for the driver alteration and platinum-based chemotherapy, with treatment failure.

The study includes a screening/baseline period, treatment period, safety follow-up (30 days after the last dose), PFS follow-up, and survival follow-up.

Study Treatments:

SYS6010: intravenous infusion 4.5 mg/kg Q3W. Docetaxel: intravenous infusion 75 mg/m² Q3W. Treatment will continue until meeting any protocol-defined treatment discontinuation criteria.

Dose modifications may include dose interruption, dose reduction, and permanent discontinuation.

Safety Assessments: Safety will be assessed from informed consent through 30 days after the last dose, including collection of all adverse events (AEs), clinical symptoms, vital signs, and laboratory abnormalities, and assessment of relationship to study treatment. Safety-related examinations (e.g., physical examination, ECOG performance status, laboratory tests) will be performed during screening/baseline and throughout treatment.

Efficacy Assessments: Tumor response will be evaluated per RECIST v1.1. The first post-randomization tumor assessment will occur at 6 weeks (+7 days). Subsequent assessments will be performed every 6 weeks (±7 days) through Week 54 (excluding the first assessment), and every 12 weeks (±7 days) from Week 55 onward, and at the end of treatment if no assessment has been performed within the prior 4 weeks. Participants who discontinue treatment prior to disease progression will enter PFS follow-up until disease progression, initiation of new anticancer therapy, death, loss to follow-up, or withdrawal (whichever occurs first).

Pharmacokinetics and Immunogenicity: Participants in the SYS6010 arm will undergo blood sampling for pharmacokinetics (PK) and immunogenicity assessments during the study.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Voluntarily participate in this clinical study, understand the study procedures, and be able to sign the written ICF ( Form); 2. Age ≥18 years, with no restriction on sex; 3. Patients with confirmed locally advanced or EGFR wild-type non-squamous non-small cell lung cancer (nsq-NSCLC). Stage IIIB or IIIC patients unsuitable for surgical resection or radical chemoradiotherapy, or Stage IV NSCLC patients. EGFR mutations (currently approved by regulatory authorities for targeted therapy) must be confirmed negative. If test results are unavailable, participants need to provide tumor tissue to undergo genetic testing.

4. Meet either of the following requirements regarding prior treatment for locally advanced or metastatic EGFR wild-type nsq-NSCLC:

  1. Driver gene-negative population must have failed only immune therapy and platinum-based chemotherapy ± anti-angiogenic therapy (limited to regimens approved by regulatory authorities).
  2. Other driver gene-positive populations must have received and failed only targeted therapy for the driver gene and platinum-based chemotherapy ± anti-angiogenic therapy (limited to first-line regimens approved by regulatory authorities).

    5. Have at least one confirmed by CT or MRI according to v1.1 criteria; 6. performance status score 0-1; 7. Expected survival ≥3 months as judged by the investigator. 8. Within 7 days before the first administration, the body organs and bone marrow function meet the requirements, defined as follows (Note: For hematological tests, participants must not have received blood component transfusion, G-CSF, TPO, TPO-RA, IL-11, or EPO within 2 weeks prior to randomization):

    1. ≥1.5×10⁹/L
    2. (PLT) ≥100×10⁹/L
    3. (HGB) ≥100 g/L
    4. Serum creatinine (Cr) ≤1.5× AND ≥50 mL/min (calculated by Cockcroft-Gault formula)
    5. Total (TBIL): ≤1.5×ULN for patients without liver metastases; ≤3×ULN for patients with Gilbert's syndrome or liver metastases
    6. /AST: ≤2.5×ULN for patients without liver metastases; ≤5×ULN for patients with liver metastases
    7. and INR ≤1.5×ULN 9. Female participants of must have a negative pregnancy test within 7 days before randomization. All participants must agree to use effective from the time of signing the ICF until 7 months after the last dose. During this period, female participants must not be breastfeeding, and male participants must refrain from sperm donation.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed small cell lung cancer, squamous cell carcinoma, neuroendocrine carcinoma, or sarcomatoid carcinoma
  2. Patients with: , brainstem , spinal cord metastasis and/or compression, or active .

    Exception: Supratentorial and/or cerebellar metastases (excluding midbrain, pons, or medulla) are allowed if: Received local therapy (e.g., radiation/surgery) Stable for ≥2 weeks before randomization (no new lesions/enlargement on imaging, stable/improved neurological symptoms). No or ≤10 mg prednisone (or equivalent) daily.

  3. Other within 3 years before randomization, except: Cured basal/squamous cell skin cancer, superficial bladder cancer, prostate/cervical carcinoma in situ.
  4. Known allergies: To any component of SYS6010 or humanized monoclonal antibodies. / to docetaxel.
  5. Residual toxicities from prior antitumor therapy > Grade 1 (per v6.0), except: Grade 2 alopecia or other toxicities deemed non-risky by investigators.
  6. Prior treatment with topoisomerase I inhibitors (including ADCs).
  7. Inadequate :

<!-- -->

  1. Major surgery (excluding ) within 4 weeks before first dose.
  2. Last antitumor therapy before first dose:

    Chemotherapy/radical radiotherapy/targeted/immunotherapy: ≥4 weeks. Small-molecule targeted drugs/TCM with antitumor claims/palliative radiotherapy/local therapy: ≥2 weeks.

  3. Within 2 weeks before first dose: IV antibiotics/antifungals/antivirals for the purpose of anti-infective therapy; strong inducers/inhibitors; OATP1B1/1B3 inhibitors.
  4. drugs/ within 4 weeks before first dose. 8. Severe cardiovascular diseases within 6 months before randomization, including: arrhythmias (e.g., ventricular arrhythmia, AV block ≥ Grade III); >470 ms (Fridericia's formula) Myocardial infarction, unstable angina, aortic dissection, angioplasty, CABG. Heart failure ≥ Class II or \<50%. Stroke or Grade ≥3 cardiovascular events. Pulmonary embolism. 9. History of ILD/non-infectious pneumonitis requiring steroids; current ILD; or suspected ILD on imaging/pulmonary function tests (severe ventilation/diffusion impairment).

10. Severe infections within 4 weeks before randomization (e.g., bacteremia, severe pneumonia, active TB); active infections requiring IV antibiotics within 2 weeks.

11. History of ulcerative colitis or Crohn's disease. 12. Pleural/pericardial effusion requiring intervention within 2 weeks. 13. Active / infection: HBV: HBsAg+ and/or HBcAb+ with HBV DNA ≥10⁴ copies/mL (or ≥2000 IU/mL).

HCV: HCV Ab+ with HCV RNA above detection limit. Note: Antiviral therapy (e.g., entecavir/tenofovir) is recommended for HBsAg+ patients before randomization.

14. Immunodeficiency (+, congenital/acquired immune disorders) or transplant history.

15. Other conditions deemed ineligible by investigators (e.g., uncontrolled psychiatric disorders, hypertension/diabetes).

Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
506 participants (estimated)

Study arms

  • Experimental
    SYS6010

    SYS6010

    Drug: SYS6010

  • Active comparator
    Docetaxel

    Docetaxel

    Drug: Docetaxel

Interventions

  • SYS6010, intravenous injection

  • Docetaxel, intravenous injection

06

What researchers measure

Primary outcomes

  1. PFS (Progression-Free Survival) assessed by IRC (Independent Review Committee) in the EGFR high-expression population.

    PFS is defined as the time from the date of randomization to the first documentation of PD as assessed by IRC per RECIST v.1.1, or death due to any cause, whichever occurs earlier.

    Time frame: Up to approximately 22 months

  2. OS (Overall Survival) in the overall population

    Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the participant is known to be alive.

    Time frame: Up to approximately 39 months

Secondary outcomes

  1. Progression Free Survival (PFS) evaluated by investigator

    PFS is defined as the time from the date of randomization to the first documentation of PD as assessed by IRC per RECIST v.1.1, or death due to any cause, whichever occurs earlier.

    Time frame: Up to approximately 22 months

  2. Objective Response Rate (ORR)

    Objective response rate is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per RECIST v.1.1.

    Time frame: Up to approximately 22 months

  3. Duration of Response (DOR)

    DOR is defined as the time from the date of the first confirmed objective response (CR or PR that is subsequently confirmed) to the date of the first documented disease progression (PD) per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: Up to approximately 22 months

  4. Disease Control Rate (DCR)

    The percentage of participants who experience a best response of CR, PR or stable disease (SD).

    Time frame: Up to approximately 22 months

  5. Incidence of adverse events

    Time frame: Up to approximately 21 months

  6. Quality of life assessed by EORTC QLQ-C30

    Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores are linearly transformed to a 0-100 scale. For Global Health Status/QoL and functional scales, higher scores indicate better health status/functioning; for symptom scales/items, higher scores indicate worse symptom burden.

    Time frame: Up to approximately 21 months

  7. Quality of life assessed by EORTC QLQ-LC13

    Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13). Scores are linearly transformed to a 0-100 scale, and higher scores indicate worse lung cancer-related symptoms (greater symptom burden).

    Time frame: Up to approximately 21 months

  8. Anti-SYS6010 antibodies (ADA)

    Incidence of SYS6010 anti-drug antibodies

    Time frame: Up to approximately 21 months

  9. EGFR protein expression lever (IHC)

    EGFR protein expression assessed by immunohistochemistry (IHC)

    Time frame: Up to approximately 21 months

  10. Exploratory Genomic Analysis by Next-Generation Sequencing (NGS)

    Tumor samples will be assessed by next-generation sequencing (NGS) to characterize genomic alterations.

    Time frame: Up to approximately 21 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2027, 21 months later.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 21 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Mar 2, 2026
StartEst.
Mar 10, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
May 30, 2031
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07442565
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 10, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Mar 4, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-EGFR Antibody-drug Conjugate CPO301

Start the discussion